Study of FB849 for adults with measurable cancer lesions
Part of Cancer clinical trials.
This early-stage trial tests whether FB849 is safe and tolerable, how the body handles it, and whether it shows any early signs of helping cancer. You may be able to join if you’re an adult with at least one measurable tumor spot and your health tests meet study requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can understand the study and sign the consent form before screening
- You’re age 18 or older
- Your scans show at least one measurable cancer lesion (tumor spot) per RECIST 1.1
- Your daily function is good (ECOG 0 or 1—mostly able to do daily activities)
- Your doctor believes you may live at least 3 months
- Your organ and blood counts from tests done within 14 days before the first dose are adequate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This Phase 1 study tests XZB-0004 in adults with solid cancers to check safety and how the body responds to the drug. It may help doctors learn whether this treatment could be useful for certain tumor types, including non-small cell lung cancer.
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
This trial tests an experimental drug called FXB0871 in people with advanced solid tumors that have stopped responding to standard treatments or for whom no standard treatment exists. The goal is to see if the drug is safe and effective, and patients who enroll will receive close monitoring throughout the study.
This Phase 1 trial studies a new cancer medicine (IBI343) that targets certain tumor cells to see how safe it is and how well it may work. You may be eligible if you have advanced, hard-to-remove cancers and your tumor has a specific marker called CLDN18.2.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.